Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(18 sites)
China
Anhui Provincial Hospital, Hefei, Anhui Lanzhou University First Hospital, Lanzhou, Gansu Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Shenzhen Second People's Hospital, Shenzhen, Guangdong The First affiliated hospital of Guangxi Medical University, Nanning, Guangxi North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei Harbin First Hospital Hematology Tumor Research Center, Harbin, Heilongjiang Henan Cancer Hospital, Zhengzhou, Henan Huazhong University of Science and Technology Union Hospital, Wuhan, Hubei Jiangsu Provincial Hospital, Nanjing, Jiangsu The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Jinan Central Clinical College of Shandong First Medical University, Jinan, Shandong Second hospital of Shanxi Medical University, Taiyuan, Shanxi Xi'an Central Hospital, Xi’an, Shanxi Sichuan Academy of Medical Sciences＆Sichuan Provincial People's Hospital, Chengdu, Sichuan Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Wenzhou People's Hospital, Wenzhou, Zhejiang